Artificial Intelligence: A Catalyst for Breakthroughs in Nanotechnology and Pharmaceutical Research

Abstract

Artificial intelligence (AI) is revolutionizing nanotechnology and pharmaceutical research by streamlining drug discovery, optimizing formulations, and personalizing treatments through predictive modelling and data analysis. Without AI, the pharmaceutical industry requires more time due to less effective drug discovery, inefficient clinical trials, and prolonged regulatory processes, resulting in higher costs and delayed treatments1. The integration of AI with nanotechnology and pharmaceutical science is revolutionizing medicine, opening up new possibilities for diagnosis, treatment, and personalized healthcare. It also enhances clinical treatments and identifies new uses for existing drugs, reducing development time and costs2. By leveraging machine learning algorithms, researchers can predict the properties and behaviour of nanomaterials, facilitating the development of nanoparticles that can deliver drugs more efficiently to specific cells or tissues3. AI accelerates nano product development by optimizing nanomaterial design, predicting nanoparticle toxicity, and enhancing nanomedicine formulation. For example, AI has been used to design nanoparticles for targeted drug delivery, improving their efficiency and safety4. AI-enabled nanotechnology can enhance molecular profiling and early diagnosis, refine the design of nanomedicines, and improve their efficacy. By optimizing nanomedicine properties, achieving effective drug synergy, and reducing nanotoxicity, AI facilitates better targetability and accelerates the development of personalized treatments.

Ähnliche Arbeiten